Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-11-01

Clinical Trial Update: Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial of revefenacin in Chinese adults with moderate to very severe chronic obstructive pulmonary disease has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Revefenacin (revefenacin)

Snippet

Sponsor: Mylan Pharma UK Ltd. | Conditions: COPD | Phase 3 | Status: COMPLETED | Results posted: 2024-11-01